


ACCURUN® 325 SERIES 200

Hepatitis B Virus DNA Positive Control



LGC Clinical Diagnostics, Inc. | 37 Birch Street, Milford, MA 01757 USA
Phone: +1 508.244.6400 | CDx-Info@LGCGroup.com

MEDIMARK® Europe
11, rue Émile Zola BP 2332
38033 Grenoble Cedex 2 – France
+ 33 (0) 4 76 86 43 22
info@medimark-europe.com

11849GB-11 October 2021

Explanation of symbols used in LGC Clinical Diagnostics product labeling



Upper limit of temperature



Temperature limitation



Authorized Representative in
the European Community



Biological risks



Use By



In Vitro Diagnostic Medical Device



Negative control



Catalogue number



Consult instructions for use



Positive control



Batch code



Manufacturer



Control



Highly Flammable



Toxic by inhalation, in contact
with skin and if swallowed



Health Hazard

ACCURUN® 325 SERIES 200 Hepatitis B Virus DNA Positive Control

NAME AND INTENDED USE

ACCURUN controls are intended to estimate laboratory testing precision and can be used to detect errors in laboratory testing procedures. ACCURUN® 325 Hepatitis B Virus DNA Positive Control Series 200 is formulated for use in genetic amplification based *in vitro* diagnostic test procedures that detect Hepatitis B Virus (HBV) DNA. Additional controls at different concentrations of HBV DNA are available separately from LGC Clinical Diagnostics.

SUMMARY

Frequent testing of independent quality control samples provides the analyst with a means of monitoring the performance of laboratory assays. Routine use of controls enables laboratories to monitor day-to-day test variation, lot-to-lot performance of test kits, and operator variation, and can assist in identifying increases in random or systematic error. A well-designed quality control program can provide added confidence in the reliability of results obtained for unknown specimens. The use of independent controls may provide valuable information concerning laboratory proficiency and kit lot variation that may affect assay sensitivity¹.

PRINCIPLES OF THE PROCEDURE

ACCURUN 325 Hepatitis B Virus DNA Positive Control Series 200 is designed for use with *in vitro* assay procedures for the purpose of monitoring test performance. ACCURUN 325 Hepatitis B Virus DNA Positive Control Series 200 is manufactured from human serum or plasma reactive for HBV DNA and nonreactive for antibodies to HIV 1 and HIV 2, HCV and HTLV. ACCURUN controls do not have assigned values. Specific levels of reactivity will vary among different manufacturers' assays, different procedures, different lot numbers and different laboratories.

REAGENTS

Item No. 2020-0096 5 vials, 4.0 ml per vial

ACCURUN 325 Hepatitis B Virus DNA Positive Control Series 200 contains stabilizers and 0.09% sodium azide as preservative.

WARNINGS AND PRECAUTIONS

For *In Vitro* Diagnostic Use.

CAUTION: Handle ACCURUN controls and all human blood products as though capable of transmitting infectious agents. ACCURUN 325 Hepatitis B Virus DNA Positive Control Series 200 is manufactured from human serum or plasma nonreactive for antibodies to HIV 1 and HIV 2, HCV and HTLV with current FDA licensed tests.

Safety Precautions

Use World Health Organization (WHO) recommended universal precautions for handling ACCURUN and human blood². Do not pipette by mouth; do not smoke, eat or drink in areas where specimens are being handled. Clean any spillage by immediately wiping up with 0.5% sodium hypochlorite solution. Dispose of all specimens, controls, and materials used in testing as though they contain infectious agents.

Handling Precautions

Do not use ACCURUN controls beyond the expiration date. To prevent formation of potentially explosive compounds due to reactions of sodium azide and copper or lead pipes, flush waste lines with large quantities of water. Nucleic acid amplification reactions are sensitive to amplicon contamination. Inconsistent or invalid results could occur if clinical specimens or quality control reagents become contaminated. Use aerosol barrier pipette tips in a biosafety hood or other containment facility for dispensing samples and controls, and open only one sample at a time. The risk of contaminating ACCURUN 325 Hepatitis B Virus DNA Positive Control Series 200 will be greatly reduced by discarding the control immediately after first use.

STORAGE INSTRUCTIONS

Store ACCURUN 325 Hepatitis B Virus DNA Positive Control Series 200 at -20°C or colder until use. To prevent leakage, store vials upright.

INDICATIONS OF REAGENT INSTABILITY OR DETERIORATION

Alterations in physical appearance may indicate instability or deterioration of ACCURUN controls. Solutions that are visibly turbid should be discarded.

PROCEDURE

Materials Provided

ACCURUN 325 Hepatitis B Virus DNA Positive Control Series 200 is manufactured from human serum or plasma reactive for HBV DNA and nonreactive for antibodies to HIV 1 and HIV 2, HCV and HTLV.

Materials Required but not Provided

Refer to instructions supplied by manufacturers of the test kits to be used.

Instructions for Use

- Prior to each use, allow the control to reach room temperature and mix by gentle inversion.
- Each vial of ACCURUN 325 should not be used more than three times and must be used within 10 days after first opening.
- Immediately after each use, refrigerate ACCURUN 325 at 2-8°C.
- When the vial is opened for the first time, record the date opened and the expiration date on the vial.
- To minimize the chance of contamination, discard the vial after first use.

ACCURUN controls should be included in a test run using exactly the same procedure provided by the manufacturer for unknown specimens. ACCURUN controls must NOT be substituted for the positive and negative control reagents provided with manufactured test kits.

Quality Control

Since ACCURUN controls do not have assigned values, it is recommended that each laboratory validate the use of each lot of ACCURUN with each specific assay system prior to its routine use in the laboratory.

INTERPRETATION OF RESULTS

Levels of reactivity of ACCURUN 325 Hepatitis B Virus DNA Positive Control Series 200 may vary with different manufacturers' tests and different test kit lots. Since the control does not have an assigned value, the laboratory must establish a range for each lot of ACCURUN 325 Hepatitis B Virus DNA Positive Control Series 200. When results for ACCURUN 325 Hepatitis B Virus DNA Positive Control Series 200 are outside the established acceptance range of values, it may be an indication of unsatisfactory test performance. Possible sources of error include: deterioration of test kit reagents, operator error, faulty performance of equipment, or contamination of reagents.

LIMITATIONS OF THE PROCEDURE

ACCURUN CONTROLS MUST NOT BE SUBSTITUTED FOR THE POSITIVE AND NEGATIVE CONTROL REAGENTS PROVIDED WITH MANUFACTURED TEST KITS.

TEST PROCEDURES and INTERPRETATION OF RESULTS provided by manufacturers of test kits must be followed closely. Deviations from procedures recommended by test kit manufacturers may produce unreliable results. ACCURUN controls are not calibrators and should not be used for assay calibration. Performance characteristics for ACCURUN 325 Hepatitis B Virus DNA Positive Control Series 200 have been established only for Hepatitis B Virus DNA. Adverse shipping and storage conditions or use of outdated controls may produce erroneous results.

EXPECTED RESULTS

ACCURUN 325 Hepatitis B Virus DNA Positive Control Series 200 DOES NOT HAVE AN ASSIGNED VALUE. This positive control is formulated for use in the manufacturer's assay listed in Table 1. Specific levels of reactivity will vary among different manufacturers' assays, different procedures, different lot numbers and different laboratories. Procedures for implementing a quality assurance program and monitoring test performance on a routine basis must be established by each individual laboratory. Each laboratory should establish its own range of acceptable values. For example, the acceptable range might include all values within 2 standard deviations of the mean of 20 data points obtained in 20 runs over a period of 30 days³.

SPECIFIC PERFORMANCE CHARACTERISTICS

ACCURUN controls are designed for use with *in vitro* assay procedures for purposes of monitoring assay performance. ACCURUN 325 Hepatitis B Virus DNA Positive Control Series 200 is manufactured from human serum or plasma reactive for HBV DNA and nonreactive for antibodies to HIV 1 and HIV 2, HCV and HTLV. ACCURUN controls do not have assigned values. Specific levels of reactivity will vary among different manufacturers' assays, different procedures, different lot numbers, and different laboratories. Procedures for implementing a quality assurance program and monitoring test performance on a routine basis must be established by each individual laboratory.

REFERENCES

1. Green IV GA, Carey RN, Westgard JO, Carlen T, Shablesky LA, Achord D, Page E, and Le AV. Quality control for qualitative assays: quantitative QC procedure designed to assure analytical quality required for an ELISA for hepatitis B surface antigen. *Clin. Chem.* 43:9 1618-1621, 1997.
2. Joint ILO/WHO Guidelines on Health Services and HIV/AIDS, 2005.
3. Statistical Quality Control for Quantitative Measurements: Principles and Definitions; Approved Guidelines—Second Edition. NCCLS document C24-A2, 1999.

Table 1. Typical data for ACCURUN 325 Hepatitis B Virus DNA Positive Control Series 200.

Manufacturer	Assay	Result
Roche Molecular Systems, Inc. Branchburg, NJ	COBAS® AmpliPrep/ COBAS® TaqMan® HBV Test v2.0	500 IU/ml
Abbott Laboratories Abbott Park, IL	m2000 RealTime HBV Assay	200 IU/ml
Grifols Diagnostic Solutions Inc Emeryville, CA	PROCLEIX® ULTRIO® Assay	Positive
Roche Molecular Systems, Inc. Branchburg, NJ	cobas TaqScreen MPX Test on s201	Positive

For assistance, contact LGC Clinical Diagnostics Technical Support at +1 508.244.6400.